Eylea HD shows real-world promise for hard-to-treat AMD patients

Switching to Eylea HD pays off for tough AMD cases

The SPECTRUM study's latest interim data offers encouraging news for patients with neovascular age-related macular degeneration (AMD) who weren't responding optimally to prior treatments. In a cohort of 1,100 previously treated patients — many of whom had been on therapy for nearly 3 years and were stuck on tight 8-week dosing schedules — switching to aflibercept 8 mg (Eylea HD) delivered meaningful improvements across key retinal health markers, with no new safety signals at 6 months.

Vision remained stable overall, and patients with very low baseline vision actually gained an average of 8.3 letters. Retinal fluid clearance more than doubled, with 43% of patients achieving a "dry" retina — a key indicator of disease control.

By the Numbers

• Central retinal thickness dropped by 30 µm on average (and 130 µm in patients with thicker baseline retinas)
• 64% of patients on ≤8-week intervals were able to extend their dosing schedule after switching
• 43% achieved complete retinal drying (no intraretinal or subretinal fluid) at 6 months
• Results were consistent whether patients switched from aflibercept 2 mg or faricimab

Why it matters: For patients with AMD who've plateaued on existing therapies, Eylea HD appears to offer a meaningful step up — improving retinal outcomes and potentially reducing the treatment burden with longer dosing intervals.